In last trading session, Akebia Therapeutics, Inc. (NASDAQ:AKBA) saw 2,726,410 shares changing hands with its beta currently measuring 1.79. Company’s recent per share price level of $3.06 trading at -$0.06 or -1.77% at ring of the bell on the day assigns it a market valuation of $469.72 Million. That closing price of AKBA’s stock is at a discount of -348.04% from its 52-week high price of $13.71 and is indicating a premium of 31.7% from its 52-week low price of $2.09. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 3.87 Million shares which gives us an average trading volume of 6.41 Million if we extend that period to 3-months.
For Akebia Therapeutics, Inc. (AKBA), analysts’ consensus is at an average recommendation of Overweight while assigning it a mean rating of 2.2. Splitting up the data highlights that, out of 8 analysts covering the stock, 1 rated the stock as a Sell while none recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 6 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.36 in the current quarter.
Akebia Therapeutics, Inc. (NASDAQ:AKBA) trade information
In the face of being in the red during last session for losing -1.77%, in the last five days AKBA remained trading in the green while hitting it’s week-highest on Wednesday, Apr 14 when the stock touched $3.19-4 price level, adding 4.08% to its value on the day. Akebia Therapeutics, Inc.’s shares saw a change of 9.29% in year-to-date performance and have moved -3.16% in past 5-day. Akebia Therapeutics, Inc. (NASDAQ:AKBA) showed a performance of -15% in past 30-days. Number of shares sold short was 21.3 Million shares which calculate 3.32 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $6.71 to the stock, which implies a rise of 119.28% to its current value. Analysts have been projecting $3 as a low price target for the stock while placing it at a high target of $10. It follows that stock’s current price would jump +226.8% in reaching the projected high whereas dropping to the targeted low would mean a loss of -1.96% for stock’s current value.
Akebia Therapeutics, Inc. (AKBA) estimates and forecasts
Statistics highlight that Akebia Therapeutics, Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company lessened -13.8% of value to its shares in past 6 months, showing an annual growth rate of -59.21% while that of industry is 17.1. Apart from that, the company came raising its revenue forecast for fiscal year 2021. The company is estimating its revenue growth to increase by 23.4% in the current quarter and calculating 75% increase in the next quarter. This year revenue growth is estimated to drop -35.2% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $42.84 Million for the same. And 6 analysts are in estimates of company making revenue of $47.03 Million in the next quarter that will end on June 01, 2021.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -3.8% during past 5 years. In 2021, company’s earnings growth rate is likely to be around -17.2% while estimates for its earnings growth in next 5 years are of 0%
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Akebia Therapeutics, Inc. (NASDAQ:AKBA)’s Major holders
Insiders are in possession of 1.36% of company’s total shares while institution are holding 68.44% percent of that, with stock having share float percentage of 69.38%. Investors also watch the number of corporate investors in a company very closely, which is 208 institutions for Akebia Therapeutics, Inc. that are currently holding shares of the company. State Street Corporation is the top institutional holder at AKBA for having 22.48 Million shares of worth $62.93 Million. And as of December 30, 2020, it was holding 14.64% of the company’s outstanding shares.
The second largest institutional holder is Wellington Management Group, LLP, which was holding about 12.59 Million shares on December 30, 2020. The number of shares represents firm’s hold over 8.2% of outstanding shares, having a total worth of $35.25 Million.
On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of March 30, 2021, the former fund manager was holding 13615231 shares of worth $46.09 Million or 8.87% of the total outstanding shares. The later fund manager was in possession of 3.7 Million shares on December 30, 2020, making its stake of worth around $10.37 Million in the company or a holder of 2.41% of company’s stock.